Literature DB >> 16246494

Eleven-year follow-up results in the delay of breast irradiation after conservative breast surgery in node-negative breast cancer patients.

Olga Vujovic1, Edward Yu, Anil Cherian, A Rashid Dar, Larry Stitt, Francisco Perera.   

Abstract

PURPOSE: This retrospective review was conducted to determine if delay in the start of radiotherapy after conservative breast surgery had any detrimental effect on local recurrence or disease-free survival in node-negative breast cancer patients. METHODS AND MATERIALS: A total of 568 patients with T1 and T2, N0 breast cancer were treated with breast-conserving surgery and breast irradiation, without adjuvant systemic therapy, between January 1, 1985 and December 31, 1992 at the London Regional Cancer Centre. The time intervals from definitive breast surgery to breast irradiation used for analysis were 0 to 8 weeks (201 patients), greater than 8 to 12 weeks (235 patients), greater than 12 to 16 weeks (91 patients), and greater than 16 weeks (41 patients). Kaplan-Meier estimates of time to local-recurrence and disease-free survival rates were calculated.
RESULTS: Median follow-up was 11.2 years. Patients in all 4 time intervals were similar in terms of age and pathologic features. No statistically significant difference was seen between the 4 groups in local recurrence or disease-free survival with surgery radiotherapy interval (p = 0.521 and p = 0.222, respectively). The overall local-recurrence rate at 5 and 10 years was 4.6% and 11.3%, respectively. The overall disease-free survival at 5 and 10 years was 79.6% and 67.0%, respectively.
CONCLUSION: This retrospective study suggests that delay in the start of breast irradiation of up to 16 weeks from definitive surgery does not increase the risk of recurrence in node-negative breast cancer patients. The certainty of these results is limited by the retrospective nature of this analysis.

Entities:  

Mesh:

Year:  2005        PMID: 16246494     DOI: 10.1016/j.ijrobp.2005.08.004

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  7 in total

1.  Optimal sequence of implied modalities in the adjuvant setting of breast cancer treatment: an update on issues to consider.

Authors:  Pelagia G Tsoutsou; Yazid Belkacemi; Joseph Gligorov; Abraham Kuten; Hamouda Boussen; Nuran Bese; Michael I Koukourakis
Journal:  Oncologist       Date:  2010-11-01

Review 2.  Timing and Delays in Breast Cancer Evaluation and Treatment.

Authors:  Richard J Bleicher
Journal:  Ann Surg Oncol       Date:  2018-07-02       Impact factor: 5.344

Review 3.  Locoregional treatment of breast cancer during pregnancy.

Authors:  Antonio Toesca; Oreste Gentilini; Fedro Peccatori; Hatem A Azim; Frederic Amant
Journal:  Gynecol Surg       Date:  2014-09-30

4.  Radiation treatment waiting times for breast cancer patients in Manitoba, 2001 and 2005.

Authors:  A L Cooke; R Appell; K Suderman; K Fradette; S Latosinsky
Journal:  Curr Oncol       Date:  2009-09       Impact factor: 3.677

5.  Assessment of Breast Cancer Treatment Delay Impact on Prognosis and Survival: a Look at the Evidence from Systematic Analysis of the Literature.

Authors:  Faustine Williams
Journal:  J Cancer Biol Res       Date:  2015-12-04

6.  The Impact of Radiotherapy Delay in Breast Conservation Patients Not Receiving Chemotherapy and the Rationale for Dichotomizing the Radiation Oncology Time-Dependent Standard into Two Quality Measures.

Authors:  Richard J Bleicher; Meena S Moran; Karen Ruth; Stephen B Edge; Jill M Dietz; Lee G Wilke; Vered Stearns; Scott H Kurtzman; Jonah Klein; Katharine A Yao
Journal:  Ann Surg Oncol       Date:  2021-07-29       Impact factor: 4.339

7.  The impact on clinical outcomes of post-operative radiation therapy delay after neoadjuvant chemotherapy in patients with breast cancer: A multicentric international study.

Authors:  Gustavo Nader Marta; Reem AlBeesh; Allan A Lima Pereira; Leandro Jonata Oliveira; Max S Mano; Tarek Hijal
Journal:  Breast       Date:  2020-08-29       Impact factor: 4.380

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.